COMMUNIQUÉS West-GlobeNewswire

ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference
29/05/2024
SOUTH SAN FRANCISCO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune [...]
Alkeus Pharmaceuticals Appoints Eric L. Trachtenberg as Chief Legal Officer
29/05/2024
Brings over two decades of biopharmaceutical legal, compliance and leadership experience CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc. today announced that Eric L. Trachtenberg, J.D., M [...]
Georgiamune Expands Cancer Treatment Pipeline with Two Novel Drugs Within Five Months of Launch
29/05/2024
Georgiamune receives U.S. FDA clearance for GIM-531 and begins phase II of clinical trial testing for GIM-122 GAITHERSBURG, Md., May 29, 2024 (GLOBE NEWSWIRE) -- Today, Georgiamune Inc. , a privately held, clinical- [...]
Helius Medical Technologies, Inc. Announces Third-Party Reimbursement for PoNS® from Major Insurance Carrier
29/05/2024
-- Reimbursement at $23,900, slightly below list price -- -- Represents a significant milestone toward increasing accessibility of PoNS -- NEWTOWN, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc [...]
TerrAscend Celebrates the Opening of its New Detroit Dispensary, GAGE 313
29/05/2024
GAGE 313 is the company’s 20th Michigan dispensary TORONTO, May 29, 2024 (GLOBE NEWSWIRE) -- TerrAscend Corp. ("TerrAscend" or the "Company") (TSX: TSND) (OTCQX: TSNDF), a leading North American cannabis company, today [...]
Ceapro Inc. Reports Financial Results for First Quarter 2024 and Provides Corporate Update
29/05/2024
– Q1 2024 marked by significant advancement of R&D projects focused on avenanthramide Phase 1-2a clinical study and the processing of yeast beta glucan along with the building of pilot scale units for PGX Technology [...]
Brain Cancer Canada Awards $80,000 towards Adolescent and Young Adult (AYA) Brain Cancer Research
29/05/2024
TORONTO, May 29, 2024 (GLOBE NEWSWIRE) -- Brain Cancer Canada (BCC) is proud to announce the final grant in a series of four issued this May for Brain Cancer Awareness Month, “Go Grey in May.” The latest $80,000.00 [...]
MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With Pulmatrix
29/05/2024
Immediate opportunity to increase capacity for formulation and early asset development in upgraded Boston area R&D space Non-cash deal includes royalty-free iSPERSE ™ technology license in exchange for access to [...]
NurExone Reports First Quarter 2024 Financial Results and Provides Corporate Update, moving forward with FDA guidelines for the Human Trials
29/05/2024
TORONTO and HAIFA, Israel, May 29, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company developing regenerative [...]
Spectral AI Set to Join Russell Microcap® Index
29/05/2024
DALLAS, May 29, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment [...]
Le flux de travail CellEDIT de Cytosurge, basé sur sa technologie exclusive FluidFM®, reçoit une validation dans une publication évaluée par des pairs.
29/05/2024
Le service CellEDIT représente un nouveau flux de travail tirant parti de la nanoinjection intranucléaire de composants CRISPR/Cas9 dans des cellules uniques, par l’intermédiaire de la technologie FluidFM. Le contrôle [...]
Cytosurge's CellEDIT Workflow, based on its Proprietary FluidFM® Technology, Receives Validation in Peer-Reviewed Publication
29/05/2024
CellEDIT Service represents a novel workflow leveraging FluidFM-mediated intranuclear nanoinjection of CRISPR/Cas9 components into single cells. Control of the amount and stoichiometry of RNP complexes could boost [...]
Artelo Biosciences Presents Highly Encouraging Data Towards Developing a Solid Dosage Form of ART12.11 at CT-CANN24
29/05/2024
ART12.11 demonstrates comparable pharmacokinetics compared to Epidiolex® SOLANA BEACH, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused [...]
Adial CEO to Present at the Spring MicroCap Rodeo Conference on June 6th
29/05/2024
GLEN ALLEN, Va., May 29, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and [...]
Intelligent Bio Solutions Successfully Completes Recruitment and Begins Subject Screening for FDA 510(k) Pharmacokinetic (PK) Study
29/05/2024
NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today [...]
Penn Presbyterian Medical Center Becomes First Hospital in the Northeast to Adopt Advanced Robotic Technology for Heart Treatment
29/05/2024
ST. LOUIS, May 29, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announces the successful treatment of the first heart rhythm [...]
RespireRx Pharmaceuticals Inc. Announces a Department of Defense Award to Fund a Phase 2 Clinical Study to Determine the Safety and Efficacy of CX1739, its Lead AMPAkine, to Improve Bladder Function in Patients with Spinal Cord Injury
29/05/2024
Glen Rock, N.J., May 29, 2024 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Markets: RSPI) (RespireRx or the Company), focused on the discovery and development of innovative and revolutionary treatments [...]
IHH reports highest ever quarterly revenue in Q1 2024, with double-digit growth across key metrics, on outstanding performance across all markets
29/05/2024
KUALA LUMPUR, Malaysia and SINGAPORE, May 29, 2024 (GLOBE NEWSWIRE) -- Revenue at RM6.0 billion mark for the first time Outstanding growth momentum: revenue up 16%, EBITDA up 19% Core profit or PATMI (ex EI) up 22%; [...]
MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference
29/05/2024
ROCKVILLE, Md., May 29, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and [...]

Pages